Quantitative prediction of the interaction of midazolam and histamine H2 receptor antagonists in rats

Drug Metabolism and Disposition

Volumn 26, Issue 4, 1998, Pages 318-323

  Takedomi, Sayuri ^b   Matsuo, Hirotami ^b   Yamano, Katsuhiro ^b   Yamamoto, Koujirou ^b   Iga, Tatsuji ^b   Sawada, Yasufumi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; MIDAZOLAM; RANITIDINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG METABOLISM; DRUG OXIDATION; INTRAVENOUS DRUG ADMINISTRATION; LIVER MICROSOME METABOLISM; MALE; METABOLIC INHIBITION; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; AREA UNDER CURVE; CIMETIDINE; DRUG INTERACTIONS; HALF-LIFE; HISTAMINE H2 ANTAGONISTS; LIVER; MALE; METABOLIC CLEARANCE RATE; MIDAZOLAM; MODELS, BIOLOGICAL; NIZATIDINE; RATS; RATS, WISTAR;

ANIMALIA;

EID: 0031892244     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulphaphenazole as the respective selective inhibitors of P450 IIIA and IIC9. Xenobiotica 25:261-270.
2. Beckmann J, Elsasser W, Gundert-Remy U and Hertrampf R (1987) Enoxacin: A potent inhibitor of theophylline metabolism. Eur J Clin Pharmacol 33:227-230.
3. Ellwood RJ, Hildebrand PJ, Dundee JW and Collier PS (1983) Ranitidine influences the uptake of oral midazolam. Br J Clin Pharmacol 15:743-745.
4. Fee JPH, Collier PS, Howard PJ and Dundee JW (1987) Cimetidine and ranitidine increase midazolam bioavailabiliry. Clin Pharmacol Ther 41:80-84.
5. Fujieda Y, Yamaoka K, Ito T and Nakagawa T (1996) Local absorption kinetics of levofloxacin from intestinal tract into portal vein in concentration difference. Pharm Res 13:1201-1204.
6. Gascon MP and Dayer P (1991) In vitro forecasting of drugs which may interfere with the biotransformation of midazolam. Eur J Clin Pharmacol 41:573-578.
7. Greenblatt DJ, Locniskar A, Scavone JM, Blyden GT, Ochs HR, Harmats JS and Shader I (1986) Absence of interaction of cimetidine and ranitidine with intravenous and oral midazolam. Anesth Analog 65:176-180.
8. Hoffman DJ, Seifert T, Borre A and Ncllans HN (1995) Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm Res 12:889-894.
9. Jurima-Romet M, Crawford K, Cry T and Inaba T (1994) Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
10. Knodell RG, Browne DG, Gwozdz GP, Brian WR and Guengerich FP (1991) Differential inhibition of individual human liver cytochrome P-450 by cimetidine. Gastroenterology 101:1680-1691.
11. Mandema JW, Tukker E and Danhof M (1991) Pharmacokinetic-pharmacodynamic modelling of EEG effects of midazolam in individual rats: Influence of rate and route of administration. Br J Pharmacol 102:663-668.
12. 2 receptor antagonists, cimetidine and nizatidine, into isolated rat hepatocytes: Contribution of type I system. J Pharmacol Exp Ther 269:1220-1227.
13. Nelson DR. Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC and Neben DW (1996) P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6:1-42.
14. Neuvonen PJ and Suhonen R (1995) Itraconazole interacts with felodipine. J Am Acad Dermatol 33:134-135.
15. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, Barr DM, Gillies BS and Thummel KE (1996) First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 60:14-24.
16. 2 receptor antagonists on drug metabolism. Biochem Pharmacol 35:4457-4461.
17. Sawada Y and Iga T (1996) Drug interaction and proper use of drugs. Pharm Monthly 38:725-750 (in Japanese).
18. Sawada Y, Takanaga H and Iga T (1996) Desirable state of Drug Interaction section in package insert circulars. J Pract Pharm 47:1535-1565 (in Japanese).
19. Shimokawa M, Yamamoto K, Kawakami J, Sawada Y and Iga T (1994) Effect of renal or hepatic dysfunction on neurotoxic convulsion induced by ranitidine in mice. Pharm Res 11:1519-1523.
20. Sugiyama Y and Iwatsubo T (1996) Alteration of pharmacokinetic features caused by drug interactions. Xenobiotic Metab Dispos 11:286-293 (in Japanese).
21. Thomsen AH, Thompson GD, Hepburn M and Whitming BA (1987) Clinically significant interaction between ciprofloxacin and theophylline. Eur J Clin Pharmacol 33:435-436.
22. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE and Shader RI (1996) Triazolam biotransformation by human liver microsomes in vitro: Effect of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 276:370-379.
23. Wacher VJ, Salphati L and Benet LZ (1996) Active secretion and enterocytic drug metabolism barrier to drug absorption. Adv Drug Delivery Rev 20:99-112.
24. Warot D, Bergougnant L, Lamiable D, Berlin I, Bensimon G, Danjou P and Puech AJ (1987) Troleandomycin-triazolam interaction in healthy volunteers: Pharmacokinetic and psychometric evaluation. Eur J Clin Pharmacol 32:389-393.
25. Wijnands WJA, Vree TB and van Herwaarden CLA (1986) The influence of quinolone derivatives on theophylline clearance. Br J Clin Pharmacol 22:677-683.
26. Wilson CM, Robinson FP, Thompson EM, Dundee JW and Elliott P (1984) The effect of ranitidine on the hypnotic action of single doses of midazolam, temazepam and zopiclone. Br J Clin Pharmacol 20:553.
27. Wright AWE (1991) Cimetidine: An inhibitor and inducer of rat liver microsomal cytochrome P-450. Xenobiotica 21:193-203.
28. Yamaoka K, Tanigawara Y, Nakagawa T and Uno T (1981) A pharmacokinetic analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 4:879-885.
29. Yamazaki M, Suzuki H and Sugiyama Y (1996) Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics. Pharm Res 13:497-513.